Comparative Pharmacology
Head-to-head clinical analysis: CONJUGATED ESTROGENS versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONJUGATED ESTROGENS versus DIETHYLSTILBESTROL.
CONJUGATED ESTROGENS vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Conjugated estrogens bind to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting estrogenic effects on target tissues, including the endometrium, breast, and bone. They increase hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin, and other proteins, and have effects on lipid metabolism, coagulation factors, and vasodilation via nitric oxide.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
0.625 mg orally once daily for menopausal symptoms; 1.25 mg orally three times daily for 2-3 weeks for abnormal uterine bleeding; 25 mg intravenously or intramuscularly every 6-12 hours for postpartum hemorrhage.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
10–24 hours (terminal); clinical context: requires daily dosing for stable hormone levels.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Renal: 40–50% as glucuronide conjugates; biliary/fecal: ~20% as free and conjugated forms.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category D/X
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."